- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01614301
Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma
A Prospective Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial of Temsirolimus in Combination With Pioglitazone, Etoricoxib and Metronomic Low-dose Trofosfamide Versus Dacarbazine (DTIC) in Patients With Advanced Melanoma
A prospective phase I and consecutive phase II, twoarm, randomized multi-center trial of temsirolimus in combination with pioglitazone, etoricoxib and metronomic low-dose trofosfamide versus dacarbazine (DTIC) in patients with advanced melanoma
Phase I: To determine the dose of temsirolimus to be used in phase II part of the study
Phase II:
To determine overall survival Secondary objectives
- To evalulate response rate
- To evaluate time to progression (TTP)
- To evalulate time to partial response (time to PR or better)(TPR)
- To evaluate quality of life
- To evaluate tolerability and safety
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Bavaria
-
Regensburg, Bavaria, Germany, 93053
- Recruiting
- University of Regensburg
-
Contact:
- Albrecht Reichle, Professor
- Phone Number: +499419440
- Email: albrecht.reichle@UKR.de
-
Sub-Investigator:
- Martin Vogelhuber, MD
-
Sub-Investigator:
- Stephanie Mayer, MD
-
Sub-Investigator:
- Christina Hart, MD
-
Sub-Investigator:
- Matthias Grube, MD
-
Sub-Investigator:
- Susanne Gantner, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- At least 18 years of age
- Must be able to adhere to the study visit schedule and other protocol requirements.
- Must be histologically diagnosed with metastatic melanoma and LDH level > 0.8 ULN
- Measurable lesions
- Subjects must receive study medication as first-line therapy. Preceeding adjuvant therapies are allowed.
- BRAF V600 mutation analysis
- Sufficient bone marrow function: neutrophils ≥ 2x109/l, hemoglobin ≥10 g/dl, platelets ≥ 100x109/l
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 (see Post Text Supplement 3).
Required laboratory results:
- Liver function: Total bilirubin < 1.5 times of upper limit of local institution (ULN), SGPT, SGOT ≤ 2.5 times of upper limit of local institution
- Renal function: serum creatinine ≤ 1.5 ULN
- PT-INR/PT <1.5 ULN
- Normal cardiac function
- Patients with prior thrombembolic event with adequate anticoagulation
- Life expectancy at least 3 months
- Written informed consent of the patient prior to screening procedures
- Patient must be available for treatment and follow-up
- Adequate contraception in women capable of bearing children and men with partner capable of bearing children (combined oral contraceptives, hormonereleasing intrauterine contraceptive device, hormonal contraceptive implants, hormonal contraceptive injectables, surgical sterilization)
- Any previous surgery must have taken place more than 4 weeks prior to inclusion
- Previous radiation therapy must have involved less than 25% of bone marrow, and must have been completed more than 4 weeks prior to inclusion.
- For patients with controlled diabetes mellitus glucose levels have to be monitored continuously and the treating diabetologist has to be informed about the study participation of the patient.
- Patients with wild-type BRAF
Exclusion Criteria:
- Documented brain metastases unless the patient has completed successful local therapy for central nervous system metastases and has been off of corticosteroids for at least 4 weeks before enrollment.
- Patients who require vitamin K antagonists except for low dose
- Patients with bladder cancer or bladder cancer in their medical history, patients with risk factors for bladder cancer (such as exposure to aromatic amines or heavy tobacco smokers), or macrohematuria of unknown origin
- Prior history of stroke
- Known hypersensitivity to study drugs or to any of the excipients
- Active infection > grade 2 NCI-CTC version 4.0
- Known diagnosis of HIV, hepatitis B, or hepatitis C infection.
- Severe, unstable, or uncontrolled medical disease which would confound diagnoses or evaluations required by the protocol, including cardiac insufficiency (NYHA I -IV) uncontrolled diabetes including diabetic ketoacidosis, chronic hepatic or renal disease, active uncontrolled infection and chronic inflammatory intestinal disease, autoimmune diseases, peripheral arterial disease, verified coronary heart disease, cerebrovascular disease, acute peptic ulcer or acute gastro-intestinal bleeding.
- Prior radiation therapy > 25% of bone marrow
- Regular blood transfusions
- Treatment with other experimental substances within 30 days before study start
- Prior immunotherapy with ipilimumab, vaccination, B-raf inhibitor
- Participation in another clinical trial within 30 days before study start or during the trial
- Unwilling or unable to comply with the protocol
- Pregnant or breastfeeding patients. Women of childbearing potential must have a negative pregnancy test performed 7 days prior start of treatment.
- Patients with seizure disorders requiring medication (such as steroids or antiepileptics)
- Patients with evidence or history of bleeding diathesis
- Patients undergoing renal dialysis
- Major surgery within 4 weeks prior to start of study or incomplete wound healing
- Drug or alcohol abuse
- Psychological or social conditions that may interfere with the patients participation in the study or evaluation of the study results.
- Known (at time of entry) gastrointestinal disorder, including malabsorbtion or active gastric ulcer, present to the extent that it might interfere with oral intake and absorption of study medication
- Patients undergoing dialysis or creatinine clearance <30 mL per minute, defined according to MDRD
- Patients with medically uncontrolled hypertension (RR continuously > 140/90 mm Hg)
- Any previous or concurrent malignancy or any cancer unless curatively treated > 3 years prior to study entry except cervical carcinoma in situ or adequate basal cell carcinoma
- Any urothelial cell carcinoma in the medical history
- Patients who have experienced bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria, or allergic type reactions after acetylsalicylic acid or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors
- Patients with BRAF V600 mutant metastatic melanoma
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental Arm
Temsirolimus: 15 or 25 mg iv weekly , week 1+.In the phase I part of the study the finally used dosis will be determined.
Pioglitazone (Actos) 60 mg p.o. daily, day 1+.
Etoricoxib (Arcoxia) 60 mg p.o. daily, day 1+ Trofosfamide (Ixoten) 50 mg p.o. thrice daily as metronomic angiostatically and immunomodulatory acting therapy, day 1+.
Treatment until disease progression or toxicity
|
Dacarbazine (DTIC) 1000 mg/m2 day 1, every 3 weeks The total number of DTIC cycles should not exceed 6 cycles due to cumulative toxicity. Temsirolimus: 15 or 25 mg iv weekly , week 1+.In the phase I part of the study the finally used dosis will be determined. Pioglitazone (Actos) 60 mg p.o. daily, day 1+. Etoricoxib (Arcoxia) 60 mg p.o. daily, day 1+. Trofosfamide (Ixoten) 50 mg p.o. thrice daily as metronomic angiostatically and immunomodulatory actingtherapy, day 1+. Treatment until disease progression or toxicity |
Other: Controll Arm
Dacarbazine (DTIC) 1000 mg/m2 day 1, every 3 weeks.
The total number of DTIC cycles should not exceed 6 cycles due to cumulative toxicity.
|
Dacarbazine (DTIC) 1000 mg/m2 day 1, every 3 weeks The total number of DTIC cycles should not exceed 6 cycles due to cumulative toxicity. Temsirolimus: 15 or 25 mg iv weekly , week 1+.In the phase I part of the study the finally used dosis will be determined. Pioglitazone (Actos) 60 mg p.o. daily, day 1+. Etoricoxib (Arcoxia) 60 mg p.o. daily, day 1+. Trofosfamide (Ixoten) 50 mg p.o. thrice daily as metronomic angiostatically and immunomodulatory actingtherapy, day 1+. Treatment until disease progression or toxicity |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
response rate
Time Frame: 2014
|
2014
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to progession
Time Frame: 2014
|
2014
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Albrecht Reichle, Professor, University of Regensburg
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Melanoma
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Cyclooxygenase 2 Inhibitors
- Pioglitazone
- Sirolimus
- Dacarbazine
- Etoricoxib
- Trofosfamide
Other Study ID Numbers
- MEL001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Melanoma
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma (Locally Advanced) | Stage IIC Melanoma (Locally Advanced) | Stage IV Melanoma (Limited, Resectable)United States
-
Regeneron PharmaceuticalsBristol-Myers SquibbCompletedMelanoma | Metastatic Melanoma | Unresectable Melanoma | Advanced MelanomaUnited States
-
Regeneron PharmaceuticalsBristol-Myers SquibbActive, not recruitingMelanoma | Metastatic Melanoma | Unresectable Melanoma | Advanced MelanomaUnited States
-
BiocadRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma AdvancedIndia, Russian Federation, Belarus
-
MorphotekTerminatedMelanoma | Metastatic Melanoma | Advanced Melanoma | Malignant Metastatic MelanomaUnited States
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Metastatic Melanoma | Advanced Non-hematologic MalignanciesUnited States
-
University of Colorado, DenverMerck Sharp & Dohme LLCActive, not recruitingStage IV Melanoma | Advanced Melanoma | Stage III MelanomaUnited States
-
Yana NajjarBristol-Myers Squibb; PfizerActive, not recruitingUnresectable Melanoma | Advanced MelanomaUnited States
-
Shanghai Junshi Bioscience Co., Ltd.UnknownMetastatic Melanoma | Advanced MelanomaChina
-
Azienda Ospedaliera di PerugiaNot yet recruitingAdvanced Melanoma | Early MelanomaItaly, Sweden, France, Germany, Netherlands, Poland, Spain